Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The primary results from the SELECT trial, published almost two years ago, showed that high-dose semaglutide (the version approved as Wegovy for treating obesity) reduced peoples risk of heart attacks and other major cardiovascular events by 20% during the study period
According to Joel Bikman, a long-time nutrition executive and the co-founder of a science-based health and wellness company, clever drug manufacturers discovered that by considerably increasing the dosages, these drugs had a powerful effect on weight loss
Originally crafted as diabetes treatment, GLP-1 inhibitors work to help manage blood sugar by slowing the amount of sugar produced by the liver in addition to, yes, slowing down the digestion of food
For example, semaglutide (sold as Ozempic, Wegovy, or Rybelsus) has been studied extensively and shown some of the most impressive weight loss results, with research from the New England Journal of Medicine showing an average weight loss of up to 15% over 68 weeks for some patients
You want roughly even intervals
268 participants who were switched to placebo at 20 weeks
US$ 23.27
US$ 28.82
US$ 24.34
US$ 24.21
US$ 20.59
US$ 24.40
